Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Arcus Biosciences, Inc. on July 7, 2020. The report discloses a material change in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the concurrent departure of the previous principal financial and accounting officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment: Robert C. Goeltz II will join as Chief Financial Officer and principal financial/accounting officer effective August 1, 2020.
- Departure: Jason Barker, currently Vice President of Finance, will cease to serve as the principal financial and accounting officer concurrent with Mr. Goeltz's appointment.
- Compensation Package for New CFO:
- Annual Base Salary: $420,000
- Annual Target Bonus: 40% of base salary
- One-time Sign-on Bonus: $80,000
- Equity Grant: Option to acquire 250,000 shares of common stock under the 2020 Inducement Plan, vesting monthly over four years.
- Severance and Change of Control: Mr. Goeltz will enter into standard agreements providing for cash severance, medical premium payments, and accelerated equity vesting in the event of termination within 12 months of a change of control. Pro-rata bonuses and severance apply to terminations without cause outside of a change of control.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies beyond the standard terms of the employment agreement. The appointment is presented as a strategic move to strengthen the finance leadership team, leveraging Mr. Goeltz's prior experience as CFO at UNITY Biotechnology, CytomX Therapeutics, and Onyx Pharmaceuticals.
Key Facts for Investor Verification
- Verify the effective start date of August 1, 2020, for Robert C. Goeltz II.
- Confirm the vesting schedule and exercise price of the 250,000 stock options granted under the 2020 Inducement Plan.
- Review the specific terms of the severance and change of control agreement to understand potential future cash outflows.
- Monitor the transition of duties from Jason Barker to ensure continuity in financial reporting.